Technology ID
TAB-4871
Monoclonal Antibodies in the Advancement of Bacillus anthracis Diagnosis and Surveillance
E-Numbers
E-049-2018-0
Lead Inventor
Leppla, Stephen
Lead IC
NIAID
ICs
NIAID
Applications
Diagnostics
Therapeutic Areas
Infectious Disease
Development Stages
Prototype
Research Products
Antibodies
Monoclonal antibodies produced by hybridomas IE5, IE9, and 13B3 are specific for the Bacillus anthracis PA20 fragment. These antibodies hold significant potential for rapid and precise Bacillus anthracis diagnosis in clinical and environmental samples. They can be employed in various diagnostic assays, offering a valuable tool for public health and biosecurity applications. Rigorous testing and validation are essential before their integration into diagnostic devices.
Commercial Applications
These monoclonal antibodies offer quick and precise Bacillus anthracis detection, aiding in emergencies and biosecurity. They also assist in vaccine development, validate diagnostic results, and contribute to research, including environmental monitoring. In short, their specificity and versatility are valuable assets in anthrax-related applications.
Competitive Advantages
These monoclonal antibodies, developed by hybridomas IE5, IE9, and 13B3, hold a unique competitive advantage due to their exceptional specificity for Bacillus anthracis. Their integration into diagnostic assays enables rapid and precise detection, providing a valuable tool for emergency responses. With a well-documented history of reliability dating back to 1988, these antibodies offer a proven and trusted solution for Bacillus anthracis diagnosis and surveillance.
Licensing Contact: